Adolor Corporation Has Agreed to be Acquired by Cubist Pharmaceuticals, Inc.

  • Do you own shares of Adolor Corporation (Nasdaq: ADLR)?
  • Did you buy any shares before October 24, 2011?
  • Do you think that the proposed buyout price is too low?
  • Do you want to discuss your rights?

If the answer to these questions is "yes," please contact the deal lawyers at Rigrodsky & Long, P.A. ("R & L") today to schedule a FREE consultation. Just call us, or fill out our contact form so that we can call at your convenience. Your consultation will not create any obligation to use our services at any time.

Contact R & L today to be sure your best interests are being protected.

R & L is national law firm with decades of combined legal experience. R & L is investigating potential claims against the board of directors of Adolor Corporation concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by Cubist Pharmeceuticals, Inc. for up to $415 million.

Click here to read the full press release.

Rigrodsky & Long, P.A. Investigates Adolor Corporation's Sale to Cubist Pharmaceuticals, Inc. for Shareholders

Rigrodsky & Long, P.A. announces that it is investigating potential claims against the board of directors of Adolor Corporation (“Adolor” or the “Company”) (Nasdaq: ADLR) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by Cubist Pharmaceuticals, Inc. (“Cubist”) in a transaction with an approximate value up to $415 million.

Under the proposed agreement, Cubist will acquire all of the outstanding shares of Adolor for $4.25 per share in cash, or approximately $190 million on a fully-diluted basis, net of Adolor’s third quarter 2011 cash balance.  In addition to the upfront cash payment, each Adolor stockholder will receive one Contingent Payment Right (“CPR”), entitling the holder to receive additional cash payments of up to $4.50 for each share they own if certain regulatory approvals and/or commercialization milestones for ADL5945 are achieved.  The total transaction is valued at up to $415 million, net of Adolor’s third quarter 2011 cash balance.  Under the proposed agreement, Cubist will commence a tender offer to purchase all of the outstanding shares of Adolor for the upfront cash payment and a CPR.

The investigation concerns whether Adolor’s board of directors adequately shopped the Company to obtain the best price possible for Adolor’s shareholders before entering into the agreement with Cubist.  Indeed, according to Yahoo! Finance, at least one analyst has set an $8.00 per share stock price for Adolor stock.

If you own the common stock of Adolor and purchased your shares before October 24, 2011, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky, Esquire or Noah R. Wortman, Case Development Director, of Rigrodsky & Long, P.A., 919 N. Market Street, Suite 980, Wilmington, Delaware 19801, by telephone at (888) 969-4242, or by e-mail to info@rigrodskylong.com.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.

R & L, with offices in Delaware and New York, litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Learn more about R&L:  Visit Our WebsiteOur Firm  |  Our Practice Areas  |  FAQ's

Fill out the form below or call us toll-free at 888-969-4242, for a FREE no-obligation consultation.